SG11201907548PA - Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same - Google Patents
Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the sameInfo
- Publication number
- SG11201907548PA SG11201907548PA SG11201907548PA SG11201907548PA SG11201907548PA SG 11201907548P A SG11201907548P A SG 11201907548PA SG 11201907548P A SG11201907548P A SG 11201907548PA SG 11201907548P A SG11201907548P A SG 11201907548PA SG 11201907548P A SG11201907548P A SG 11201907548PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- dohme corp
- chiyoda
- chome
- tokyo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 30 August 2018 (30.08.2018) WIP0 I PCT omit VIII °nolo OH loom!! VIII 1110110111110 Hs (10) International Publication Number WO 2018/154390 Al (51) International Patent Classification: C07K 16/18 (2006.01) C07K 16/44 (2006.01) (21) International Application Number: PCT/IB2018/000249 (22) International Filing Date: 27 February 2018 (27.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: JP 2017-035594 27 February 2017 (27.02.2017) JP (71) Applicants: TEIJIN PHARMA LIMITED [JP/JP]; 2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo, 100-0013 (JP). MERCK SHARP & DOHME CORP. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (72) Inventors: EGUCHI, Hiroshi; c/o Teijin Pharma Limited, 2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo, 100-0013 (JP). MURAKAMI, Takashi; c/o Teijin Pharma Limited, 2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo, 100-0013 (JP). NAMIKI, Naoko; c/o Teijin Pharma Limited, 2-1, Ka- sumigaseki 3-chome, Chiyoda-ku, Tokyo, 100-0013 (JP). TANOKURA, Akira; c/o Teijin Pharma Limited, 2-1, Ka- sumigaseki 3-chome, Chiyoda-ku, Tokyo, 100-0013 (JP). BAKER, Jeanne, E.; c/o Merck Sharp & Dohme Corp., 901 S. Califrnia Avenue, Palo Alto, CA 94304 (US). PARMENTIER BATTEUR, Sophie; c/o Merck Sharp & Dohme Corp., 770 Surrmeytown Pike, West Point, PA 19486 (US). JABLONSKI, Angela, Marie; c/o Merck Sharp & Dohme Corp., 770 Sumneytown Pike, West Point, PA 19486 (US). MALASHOCK, Daniel, Stephen; c/o Merck Sharp & Dohme Corp., 901 S. Califrnia Avenue, Pa- lo Alto, CA 94304 (US). MIECZKOWSKI, Carl; c/o Mer- ck Sharp & Dohme Corp., 901 S. Califrnia Avenue, Palo Al- to, CA 94304 (US). RAGHUNATHAN, Gopalan (raghu); c/o Merck Sharp & Dohme Corp., 901 S. Califrnia Avenue, Palo Alto, CA 94304 (US). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, O TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) with amended claims (Art. 19(1)) with sequence listing part of description (Rule 5.2(a)) GO (54) Title: HUMANIZED ANTIBODY FOR TREATING OR PREVENTING COGNITIVE DISORDERS, PROCESS FOR PRO- DUCING THE SAME, AND AGENT FOR TREATING OR PREVENTING COGNITIVE DISORDERS USING THE SAME \" (57) : The invention provides methods for using and compositions of humanized antibodies that bind tau protein that is phos- C phorylated at the serine at position 413.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017035594A JP2018139530A (en) | 2017-02-27 | 2017-02-27 | Humanized antibody for treating or preventing dementia and production method therefor and therapeutic agent or prophylactic agent for dementia using same |
| PCT/IB2018/000249 WO2018154390A1 (en) | 2017-02-27 | 2018-02-27 | Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907548PA true SG11201907548PA (en) | 2019-09-27 |
Family
ID=62025891
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913419TA SG10201913419TA (en) | 2017-02-27 | 2018-02-27 | Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same |
| SG11201907548PA SG11201907548PA (en) | 2017-02-27 | 2018-02-27 | Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913419TA SG10201913419TA (en) | 2017-02-27 | 2018-02-27 | Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10556950B2 (en) |
| EP (1) | EP3585810A1 (en) |
| JP (3) | JP2018139530A (en) |
| KR (1) | KR20190122674A (en) |
| CN (2) | CN110382528A (en) |
| AR (2) | AR110875A1 (en) |
| AU (1) | AU2018224390A1 (en) |
| BR (1) | BR112019016490A2 (en) |
| CA (1) | CA3052538A1 (en) |
| CL (2) | CL2019002296A1 (en) |
| CO (1) | CO2019008786A2 (en) |
| CR (1) | CR20190363A (en) |
| DO (1) | DOP2019000215A (en) |
| EA (1) | EA201991726A1 (en) |
| GE (1) | GEP20227392B (en) |
| IL (1) | IL267945A (en) |
| JO (1) | JOP20180014A1 (en) |
| MA (1) | MA47608A (en) |
| MX (1) | MX2019009945A (en) |
| MY (1) | MY193821A (en) |
| NI (1) | NI201900086A (en) |
| PE (1) | PE20191614A1 (en) |
| PH (1) | PH12019501929A1 (en) |
| SG (2) | SG10201913419TA (en) |
| TW (1) | TW201843179A (en) |
| WO (2) | WO2018154392A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110520440A (en) | 2017-02-17 | 2019-11-29 | 戴纳立制药公司 | Anti- τ antibody and its application method |
| JOP20180014A1 (en) * | 2017-02-27 | 2019-01-30 | Teijin Pharma Ltd | Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same |
| TW202340244A (en) | 2017-10-16 | 2023-10-16 | 日商衛材R&D企管股份有限公司 | Anti-tau antibodies and uses thereof |
| AU2020325770B2 (en) * | 2019-08-06 | 2022-08-25 | Aprinoia Therapeutics Limited | Antibodies that bind to pathological tau species and uses thereof |
| EP4159860A1 (en) * | 2020-06-02 | 2023-04-05 | Teijin Pharma Limited | Anti-igf-1 receptor humanized antibody |
| AU2021297873A1 (en) | 2020-06-25 | 2023-02-09 | Merck Sharp & Dohme Llc | High affinity antibodies targeting tau phosphorylated at serine 413 |
| WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS587390B2 (en) | 1975-03-11 | 1983-02-09 | ツキシマキカイ カブシキガイシヤ | arc |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JP4124480B2 (en) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | Immunoglobulin variants |
| JP3587390B2 (en) | 1994-03-17 | 2004-11-10 | タカラバイオ株式会社 | Phosphorylated amino acid derivative and phosphorylated peptide synthesis method |
| US7754497B2 (en) | 2003-08-29 | 2010-07-13 | Reverse Proteomics Research Institute Co., Ltd. | Method for immobilizing proteins |
| EP1697741A4 (en) | 2003-12-04 | 2008-02-13 | Xencor Inc | Methods of generating variant proteins with increased host string content and compositions thereof |
| UA107571C2 (en) | 2009-04-03 | 2015-01-26 | PHARMACEUTICAL COMPOSITION | |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| CN103502272B (en) * | 2010-10-07 | 2016-06-15 | Ac免疫有限公司 | Identify the phosphorylation specific antibody of Tau |
| SI2627672T1 (en) * | 2010-10-11 | 2018-10-30 | Biogen International Neuroscience Gmbh | Human anti-tau antibodies |
| MY186066A (en) | 2011-12-20 | 2021-06-18 | Janssen Biotech Inc | Anti-phf-tau antibodies and their uses |
| US20150183854A1 (en) | 2012-05-31 | 2015-07-02 | Teijin Pharma Limited | Therapeutic agent or prophylactic agent for dementia |
| BR112015003326A2 (en) * | 2012-08-16 | 2017-07-04 | Ipierian Inc | methods of treatment of a tauopathy |
| PT2935326T (en) | 2012-12-21 | 2020-09-14 | Biogen Ma Inc | Human anti-tau antibodies |
| ES2800827T3 (en) | 2013-06-10 | 2021-01-04 | Ipierian Inc | Treatment procedures for a tauopathy |
| SI3083680T1 (en) | 2013-12-20 | 2020-06-30 | F. Hoffmann-La Roche Ag | Humanized anti-tau(ps422) antibodies and methods of use |
| AR100978A1 (en) * | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME |
| TWI734975B (en) * | 2014-06-27 | 2021-08-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | Humanized anti-tau antibodies |
| US10208120B2 (en) | 2014-11-05 | 2019-02-19 | Genentech, Inc. | Anti-FGFR2/3 antibodies and methods using same |
| WO2016112078A2 (en) | 2015-01-08 | 2016-07-14 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
| CN107849105B (en) | 2015-07-06 | 2021-09-17 | Ucb生物制药有限责任公司 | TAU binding antibodies |
| NZ738058A (en) | 2015-07-06 | 2021-07-30 | UCB Biopharma SRL | Tau-binding antibodies |
| JO3711B1 (en) | 2015-07-13 | 2021-01-31 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
| JOP20180014A1 (en) | 2017-02-27 | 2019-01-30 | Teijin Pharma Ltd | Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same |
-
2017
- 2017-02-27 JO JOP/2018/0014A patent/JOP20180014A1/en unknown
- 2017-02-27 JP JP2017035594A patent/JP2018139530A/en active Pending
-
2018
- 2018-02-25 WO PCT/IB2018/000267 patent/WO2018154392A1/en active Application Filing
- 2018-02-26 TW TW107106444A patent/TW201843179A/en unknown
- 2018-02-27 CA CA3052538A patent/CA3052538A1/en active Pending
- 2018-02-27 EP EP18718907.1A patent/EP3585810A1/en active Pending
- 2018-02-27 WO PCT/IB2018/000249 patent/WO2018154390A1/en active Application Filing
- 2018-02-27 JP JP2019545918A patent/JP7165996B2/en active Active
- 2018-02-27 MA MA047608A patent/MA47608A/en unknown
- 2018-02-27 AU AU2018224390A patent/AU2018224390A1/en active Pending
- 2018-02-27 SG SG10201913419TA patent/SG10201913419TA/en unknown
- 2018-02-27 KR KR1020197024146A patent/KR20190122674A/en not_active Application Discontinuation
- 2018-02-27 MY MYPI2019004787A patent/MY193821A/en unknown
- 2018-02-27 GE GEAP201815170A patent/GEP20227392B/en unknown
- 2018-02-27 BR BR112019016490A patent/BR112019016490A2/en unknown
- 2018-02-27 CR CR20190363A patent/CR20190363A/en unknown
- 2018-02-27 SG SG11201907548PA patent/SG11201907548PA/en unknown
- 2018-02-27 CN CN201880008302.XA patent/CN110382528A/en active Pending
- 2018-02-27 AR ARP180100454A patent/AR110875A1/en unknown
- 2018-02-27 MX MX2019009945A patent/MX2019009945A/en unknown
- 2018-02-27 US US15/906,773 patent/US10556950B2/en active Active
- 2018-02-27 CN CN202010117151.0A patent/CN111320695B/en active Active
- 2018-02-27 PE PE2019001541A patent/PE20191614A1/en unknown
- 2018-02-27 EA EA201991726A patent/EA201991726A1/en unknown
-
2019
- 2019-07-09 IL IL267945A patent/IL267945A/en unknown
- 2019-08-09 NI NI201900086A patent/NI201900086A/en unknown
- 2019-08-13 CO CONC2019/0008786A patent/CO2019008786A2/en unknown
- 2019-08-13 CL CL2019002296A patent/CL2019002296A1/en unknown
- 2019-08-15 DO DO2019000215A patent/DOP2019000215A/en unknown
- 2019-08-20 PH PH12019501929A patent/PH12019501929A1/en unknown
- 2019-08-22 AR ARP190102386A patent/AR117952A2/en unknown
-
2020
- 2020-01-17 US US16/746,725 patent/US10894829B2/en active Active
- 2020-12-15 US US17/122,325 patent/US11739143B2/en active Active
-
2021
- 2021-09-13 CL CL2021002389A patent/CL2021002389A1/en unknown
-
2022
- 2022-10-18 JP JP2022166859A patent/JP2023002670A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907548PA (en) | Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same | |
| SG11201909081YA (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
| SG11201907754RA (en) | Anti-phf-tau antibodies and uses thereof | |
| SG11201810697QA (en) | Chimeric antigen receptor and car-t cells that bind bcma | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201804127SA (en) | Ctla4 binders | |
| SG11201810149VA (en) | Anti hla-g specific antibodies | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
| SG11201807677YA (en) | Antibodies to cd40 with enhanced agonist activity | |
| SG11201806542PA (en) | Anti-mica antibodies | |
| SG11201903693QA (en) | Polypeptide variants and uses thereof | |
| SG11201906961UA (en) | Polypeptide variants and uses thereof | |
| SG11201805579SA (en) | Recombinant igg fc multimers | |
| SG11201809764XA (en) | Humanized anti-il-1r3 antibodies | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201900744SA (en) | Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them | |
| SG11201908744PA (en) | Anti-c5a antibodies and uses thereof | |
| SG11201907927SA (en) | Binding molecules that specifically bind to tau |